These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1423177)

  • 21. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years.
    Niimoto M; Hattori T; Tamada R; Sugimachi K; Inokuchi K; Ogawa N
    Jpn J Surg; 1988 Nov; 18(6):681-6. PubMed ID: 3150019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
    J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
    Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
    Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
    Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial.
    Tormey DC; Gray R; Abeloff MD; Roseman DL; Gilchrist KW; Barylak EJ; Stott P; Falkson G
    J Clin Oncol; 1992 Dec; 10(12):1848-56. PubMed ID: 1453199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
    Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
    J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of UFT plus Tamoxifen for Estrogen-Receptor-Positive Breast Cancer and Tamoxifen plus UFT for Estrogen-Receptor-Negative Breast Cancer : Adjuvant Therapy after Administration of Mitomycin.
    Ogita M; Uchino J; Asaishi K; Kubo Y; Tanabe T; Hata A; Hirata K; Mito M;
    Clin Drug Investig; 2003; 23(11):689-99. PubMed ID: 17536882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Appraisal of adjuvant chemoendocrine therapy with tamoxifen plus tegafur in patients with breast cancer.
    Enomoto K; Fujiwara K; Ikeda T; Katoh S; Abe O
    Keio J Med; 1991 Sep; 40(3):123-8. PubMed ID: 1753554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer--five-year survival rate].
    Nakajima T; Inokuchi K; Hattori T; Inoue K; Taguchi T; Kondou T; Abe O; Kikuchi K; Tanabe T; Ogawa N
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 1):799-806. PubMed ID: 2496668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
    J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up.
    Fohlin H; Nordenskjöld A; Rosell J; Fernö M; Fornander T; Rydén L; Skoog L; Nordenskjöld B; Stål O
    Acta Oncol; 2024 Jul; 63():535-541. PubMed ID: 38967128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
    Miyake Y; Nishimura J; Kato T; Ikeda M; Tsujie M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Surg Today; 2018 Jan; 48(1):66-72. PubMed ID: 28634730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.
    Yokoe T; Iino Y; Takei H; Horiguchi J; Koibuchi Y; Maemura M; Ohwada S; Morishita Y
    Anticancer Res; 1997; 17(4A):2815-8. PubMed ID: 9252721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
    Dubsky PC; Jakesz R; Mlineritsch B; Pöstlberger S; Samonigg H; Kwasny W; Tausch C; Stöger H; Haider K; Fitzal F; Singer CF; Stierer M; Sevelda P; Luschin-Ebengreuth G; Taucher S; Rudas M; Bartsch R; Steger GG; Greil R; Filipcic L; Gnant M
    J Clin Oncol; 2012 Mar; 30(7):722-8. PubMed ID: 22271481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.
    Li HC; Wen XF; Hou YF; Shen KW; Wu J; Lu JS; Shen ZZ; Shao ZM
    Asian J Surg; 2003 Jul; 26(3):163-8. PubMed ID: 12925292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
    Fisher B; Redmond C; Legault-Poisson S; Dimitrov NV; Brown AM; Wickerham DL; Wolmark N; Margolese RG; Bowman D; Glass AG
    J Clin Oncol; 1990 Jun; 8(6):1005-18. PubMed ID: 2189950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.